NADAC acquisition cost data for TRULANCE 3 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 65649000330 | $16.27 | 2022-01-01 | Rx |
| 70194000330 | $16.27 | 2022-01-01 | Rx |
| 65649000330 | $16.27 | 2022-01-01 | Rx |
| 70194000330 | $16.27 | 2022-01-01 | Rx |
| 65649000330 | $16.27 | 2022-01-01 | Rx |
| 70194000330 | $16.27 | 2022-01-01 | Rx |
| 65649000330 | $16.27 | 2022-01-01 | Rx |
| 70194000330 | $16.27 | 2022-01-01 | Rx |
| 65649000330 | $16.27 | 2022-01-01 | Rx |
| 70194000330 | $16.27 | 2022-01-01 | Rx |
Generic: Plecanatide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $30.9M | 56,956 | 16,477 | $13.91 |
| 2020 | $48.1M | 80,431 | 22,428 | $14.57 |
| 2021 | $71.7M | 108,771 | 30,508 | $15.98 |
| 2022 | $88.9M | 122,298 | 35,495 | $17.43 |
| 2023 | $119.3M | 148,020 | 41,836 | $18.72 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $13.2M | 17,841 | 4,615 |
| New York | $13.1M | 17,034 | 4,545 |
| Texas | $8.8M | 10,404 | 3,486 |
| Florida | $6.7M | 7,772 | 2,488 |
| North Carolina | $5.9M | 7,079 | 1,972 |
| Alabama | $5.2M | 6,137 | 2,018 |
| New Jersey | $4.9M | 5,436 | 1,632 |
| Ohio | $4.5M | 5,649 | 1,574 |
| Pennsylvania | $4.5M | 5,732 | 1,523 |
| Kentucky | $4.3M | 4,613 | 1,428 |
| Illinois | $3.6M | 4,495 | 1,250 |
| Georgia | $3.5M | 4,244 | 1,316 |
| Massachusetts | $3.3M | 4,667 | 1,056 |
| Louisiana | $3.0M | 4,346 | 1,238 |
| South Carolina | $3.0M | 3,816 | 1,099 |
| Tennessee | $3.0M | 3,592 | 1,065 |
| Connecticut | $2.8M | 3,143 | 905 |
| Virginia | $2.1M | 2,504 | 729 |
| Indiana | $2.1M | 2,348 | 727 |
| Missouri | $2.0M | 2,588 | 672 |
| Wisconsin | $1.8M | 2,279 | 629 |
| Arizona | $1.7M | 1,967 | 642 |
| Michigan | $1.7M | 2,071 | 623 |
| Maryland | $1.5M | 1,646 | 538 |
| Mississippi | $1.3M | 1,590 | 480 |
| Oklahoma | $1.3M | 1,667 | 463 |
| Colorado | $1.2M | 1,699 | 462 |
| Washington | $995.6K | 1,310 | 359 |
| Arkansas | $965.5K | 1,259 | 320 |
| West Virginia | $825.0K | 999 | 318 |
| Kansas | $789.0K | 1,046 | 283 |
| Minnesota | $657.2K | 762 | 211 |
| Nevada | $570.5K | 679 | 218 |
| Utah | $524.5K | 612 | 196 |
| Nebraska | $497.5K | 652 | 174 |
| Iowa | $467.2K | 631 | 164 |
| New Hampshire | $391.5K | 507 | 130 |
| Rhode Island | $366.0K | 504 | 123 |
| Maine | $341.1K | 378 | 116 |
| Oregon | $289.9K | 403 | 132 |
| Idaho | $238.2K | 343 | 92 |
| South Dakota | $190.5K | 283 | 65 |
| Delaware | $187.7K | 208 | 67 |
| New Mexico | $157.2K | 221 | 61 |
| District of Columbia | $143.2K | 139 | 48 |
| Montana | $116.9K | 137 | 37 |
| Alaska | $91.1K | 117 | 29 |
| Puerto Rico | $78.7K | 123 | 55 |
| North Dakota | $74.0K | 101 | 31 |
| Hawaii | $62.2K | 75 | 22 |
| Vermont | $61.4K | 68 | 24 |
| Wyoming | $41.0K | 50 | 15 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.